UPDATE: Stifel Starts Obalon Therapeutics (OBLN) at Buy

October 31, 2016 7:54 AM EDT
Get Alerts OBLN Hot Sheet
Price: $11.33 +0.18%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade OBLN Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
(Updated - October 31, 2016 8:42 AM EDT)

Stifel initiated coverage on Obalon Therapeutics (NASDAQ: OBLN) with a Buy rating and a price target of $18.

Analyst Rick Wise said, "This target ascribes a 4.5x EV/R multiple applied to our 2020E, $96M revenue projection, discounted 18% to year-end 2017. Obalon appears poised for dramatic top-line growth with its highly-differentiated intragastric balloon system, already FDA-approved to treat 30-40 BMI range obese patients. The Obalon Balloon's procedural ease-of use, best-in-class patient tolerability, and excellent clinical data are likely to be compelling adoption-drivers. With US launch slated for early 2017, Obalon clearly still is in the earliest stages of commercialization. Over the next five years, assuming a solid launch and commercial execution, we project a near triple-digit sales CAGR and ultimately ~80% GMs."

For an analyst ratings summary and ratings history on Obalon Therapeutics click here. For more ratings news on Obalon Therapeutics click here.

Shares of Obalon Therapeutics closed at $13.80 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Related Entities


Add Your Comment